Filter Results:
(926)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (779)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
Show Results For
- All HBS Web
(926)
- People (2)
- News (70)
- Research (779)
- Events (1)
- Multimedia (2)
- Faculty Publications (668)
- 02 Oct 2000
- Research & Ideas
The Dubious Logic of Global Megamergers
The assumption that industries will become more concentrated as they become more global, that the global economy is a winner-take-all economy, has become common wisdom. But, according to Pankaj Ghemawat and Fariborz Ghadar, empirical... View Details
Keywords: by Pankaj Ghemawat & Fariborz Ghadar
- Profile
Paul Wang
work with the MIT’s Abdul Latif Jameel Poverty Action Lab (J-PAL). “They’re a group of economists who use randomized evaluation methodologies, similar to those used in pharmaceutical trials, to assess the impact of development projects,”... View Details
- 01 Sep 2015
- Blog Post
Building a Startup at HBS
Our group initially came together through a deep passion for health care – with the goal of creating a novel product that addressed an unmet need and made a tangible difference in patients’ lives. We felt that if we combined our prior experiences in the View Details
- 01 Dec 2020
- News
The Complete Package
school, she got a job in a hotel sales department and decided to defer her education. Two years later, Pfizer headhunted Chong. She didn’t know the number of chambers in the heart, she admitted during her interview with the pharmaceutical... View Details
Keywords: April White; entrepreneurship; sustainability; packaging; leadership; women; Manufacturing
- Profile
Thomas Grenier
yourself." The program has also opened up cultural perspectives. Thomas says, "In classes, we talk a great deal about the European emphasis on government regulation and the American belief in free trade. But the United States is where the banking View Details
- Profile
Carter Romansky
The creative side of the pharmaceutical industry engaged Carter Romansky in every aspect of the business: science, marketing, finance, law. But when his job became "less about its original goal... View Details
- Profile
Thomas Grenier
as well. Through coursework and networking opportunities during my HBS experience, I received a lot of career advice, learned key industry knowledge, made contacts and, most importantly, came to appreciate everyone's passion for what they... View Details
- 05 Jul 2004
- Research & Ideas
Radical Change, Entrepreneurial Opportunity
strategies of companies within those industries. In particular, I focus on how an industry gets defined: how consumers and other industry players make sense of, or frame, the industry, and the way that... View Details
- Profile
Rocio Parra
Why was getting a business education important to you? As a consultant, I had the opportunity to work in a variety of industries from pharmaceuticals and medical devices to government and consumer packaged... View Details
Keywords: Retail
- May 2013 (Revised October 2014)
- Case
Novartis: Leading a Global Enterprise
By: William W. George, Krishna G. Palepu and Carin-Isabel Knoop
Novartis, the world's leading healthcare company, was formed in 1996 out of a merger of two very different, mid-tier Switzerland-based pharma companies. The case traces the company's evolution over the past 17 years, as it transformed into a truly global enterprise... View Details
Keywords: Multinational Firms and Management; Talent and Talent Management; Organizational Structure; Organizational Culture; Success; Globalized Markets and Industries; Management Teams; Change Management; Business History; Mergers and Acquisitions; Global Strategy; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
George, William W., Krishna G. Palepu, and Carin-Isabel Knoop. "Novartis: Leading a Global Enterprise." Harvard Business School Case 413-096, May 2013. (Revised October 2014.)
- 28 Oct 2014
- First Look
First Look: October 28
are less responsive to changes in investment opportunities, especially in industries in which stock prices are most sensitive to earnings news. These findings are consistent with the notion that short-termist pressures distort investment... View Details
Keywords: Carmen Nobel
- 01 Jun 2000
- News
The Business of Biotech
is not a postdoc lab, this is a business. It's not enough just to do the experiment; somebody's got to take the ball and run with it." Lately, competition in the biotech industry has become more heated than ever, as a steadily increasing... View Details
Keywords: Julia Hanna
- 01 Apr 1999
- News
Q & A: Confronting New Technologies: When Doing Right Is Wrong
industries or certain segments of the pharmaceutical business. But in many other industries - financial services, education, and health care, for instance - this analytical... View Details
- 14 Dec 2010
- First Look
First Look: Dec. 14
Working PapersThe Influence of Prior Industry Affiliation on Framing in Nascent Industries: The Evolution of Digital Cameras Authors:Mary J. Benner and Mary Tripsas Abstract New industries sparked by... View Details
Keywords: Sean Silverthorne
- 06 May 2008
- First Look
First Look: May 6, 2008
business model, one that positioned the company simultaneously in the PC industry and the consumer electronics industry. While Apple enjoyed a high market share in digital media players and in online music sales, it remained a niche... View Details
Keywords: Martha Lagace
- November 1969 (Revised February 1973)
- Background Note
Note on the U.S. Prescription Drug Industry, Part II
By: Hugo Uyterhoeven and Audrey T. Sproat
Uyterhoeven, Hugo, and Audrey T. Sproat. "Note on the U.S. Prescription Drug Industry, Part II." Harvard Business School Background Note 370-039, November 1969. (Revised February 1973.)
- April 1998
- Case
Cephalon, Inc.
By: Peter Tufano
In early 1997, Cephalon, awaited an FDA panel's decision on whether its drug, Myotrophin, would be approved. If the drug was approved, the firm might need substantial additional funds to commercialize as well as to buy back rights to it (which had been sold earlier to... View Details
Keywords: Risk Management; Financing and Loans; Health Care and Treatment; Pharmaceutical Industry; United States
Tufano, Peter, Geoffrey Verter, and Markus Mullarkey. "Cephalon, Inc." Harvard Business School Case 298-116, April 1998.
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
Keywords: Health Testing and Trials; Governing Rules, Regulations, and Reforms; Valuation; Product Development; Pharmaceutical Industry
Chandra, Amitabh, and Lauren Gunasti. "Biogen and the Aduhelm Melee." Harvard Business School Case 623-046, June 2023. (Revised July 2024.)
- June 2020
- Case
Breakthroughs at Blueprint Medicines
By: Richard G. Hamermesh, Kathy Giusti and Susie L. Ma
Precision medicine company Blueprint Medicines was building a successful track record for bringing drug therapies to market 40% faster than average. The company had spent $40 million dollars and two years building a compound library that became its drug development... View Details
Keywords: Precision Medicine; Cancer; Biotechnology; Drug Development; Strategy; Expansion; Science; Genetics; Information Technology; Entrepreneurship; Organizational Culture; Management; Growth and Development; Pharmaceutical Industry; United States; Cambridge; Massachusetts
Hamermesh, Richard G., Kathy Giusti, and Susie L. Ma. "Breakthroughs at Blueprint Medicines." Harvard Business School Case 820-001, June 2020.